Lipella is a privately-held biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis, as well as improved surveillance and imaging of patients with a history of transitional cell carcinoma. We are also applying our proprietary drug delivery to the oral mucosa for the treatment of oral lichen planus.
Our lead product, LP-10 is currently in a phase-2, multi-center clinical trial, and our pipeline asset, LP-310, recently received FDA Type-B Pre-IND guidance. We maintain a pipeline of additional product candidates consistent with our strategy of developing proprietary 505(b)(2) assets that address highly-morbid indications where no adequate treatment(s) exists.
Our lead product, LP-10 is currently in a phase-2, multi-center clinical trial, and our pipeline asset, LP-310, recently received FDA Type-B Pre-IND guidance. We maintain a pipeline of additional product candidates consistent with our strategy of developing proprietary 505(b)(2) assets that address highly-morbid indications where no adequate treatment(s) exists.
Services
The following is a link to the Radiation Cystitis Patient Registry. If you are a cancer survivor with a history of pelvic radiation therapy, please consider joining the registry.
The potential uses of this registry about radiation cystitis (and cancer survivorship post-radiotherapy) include: improving the scientific understanding of radiation cystitis, discovering trends and common needs of registry participants, describing the aggregate personal characteristics of patients within the registry, documenting registry patient medical histories, and contacting registry participants to inform them of new studies.
The potential uses of this registry about radiation cystitis (and cancer survivorship post-radiotherapy) include: improving the scientific understanding of radiation cystitis, discovering trends and common needs of registry participants, describing the aggregate personal characteristics of patients within the registry, documenting registry patient medical histories, and contacting registry participants to inform them of new studies.
Dr. Kaufman co-founded Lipella, helped co-found Knopp Biosciences, which signed a deal with Biogen Idec for $345M, and served as CFO of Semprus Biosciences, which sold to Teleflex for $80M. Prior to academia, Dr. Kaufman held leadership positions Merck's & Co. Inc., and served as consultant to Smithkline Beecham (now GSK).
Reviews
Be the first to review Lipella Pharmaceuticals.
Write a Review
